- Home
- IRD
as 02-04-2025 2:34pm EST
Stocks
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FARMINGTON HILLS |
| Market Cap: | 36.1M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 159.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $2.77 | Next Earning Date: | 02-15-2025 |
| Revenue: | $8,381,000 | Revenue Growth: | -85.35% |
| Revenue Growth (this year): | -19.82% | Revenue Growth (next year): | 29.37% |
Latest OPUS GENETICS INC News
IRD Breaking Stock News: Dive into IRD Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 12/31/2024
GlobeNewswire
2 months ago
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
GlobeNewswire
2 months ago
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
TipRanks
3 months ago
Opus Genetics reinstated with a Buy at H.C. Wainwright
GlobeNewswire
3 months ago
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
3 months ago
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
Compare IRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRD OPUS GENETICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.